Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
As of today (2026-08-31), TFBS Bioscience's 14-Day RSI is 51.15.
The industry rank for TFBS Bioscience's 14-Day RSI or its related term are showing as below:
ROCO:6939's 14-Day RSI is ranked better than 52.97% of 219
companies
in the Medical Diagnostics & Research industry
Industry Median: 52.69
vs ROCO:6939: 51.15
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
TFBS Bioscience 14-Day RSI Related Terms
ROCO:6939 vs TMO, DHR, NTRA: 14-Day RSI Comparison
For the Diagnostics & Research subindustry, TFBS Bioscience's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TFBS Bioscience 14-Day RSI vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, TFBS Bioscience's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where TFBS Bioscience's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TFBS Bioscience (ROCO:6939) has a 14-Day RSI of 51.15 as of Aug. 31, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on TFBS Bioscience and its competitors. According to the industry distribution chart, TFBS Bioscience ranks #103 out of 219 companies in the Medical Diagnostics & Research industry, placing it in the top 47%.
Is TFBS Bioscience's 14-Day RSI too high?
TFBS Bioscience's current 14-Day RSI is 51.15. The Medical Diagnostics & Research industry median 14-Day RSI is 52.69. TFBS Bioscience's value of 51.15 is 2.9% below this industry median. Based on the distribution chart, TFBS Bioscience ranks #103 out of 219 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, TFBS Bioscience has a GF Score™ of 54/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does TFBS Bioscience's 14-Day RSI compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, TFBS Bioscience ranks #103 out of 219 companies for 14-Day RSI. This puts TFBS Bioscience in the upper half of its industry. The industry median 14-Day RSI is 52.69. TFBS Bioscience's value of 51.15 is 2.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Medical Diagnostics & Research company?
The median 14-Day RSI among Medical Diagnostics & Research companies is 52.69, based on 219 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TFBS Bioscience's current 14-Day RSI of 51.15 is 2.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on TFBS Bioscience and its competitors. For the Medical Diagnostics & Research industry, the median 14-Day RSI is 52.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TFBS Bioscience's current 14-Day RSI is 51.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TFBS Bioscience stock overvalued right now?
Based on GuruFocus' analysis, TFBS Bioscience (ROCO:6939) is currently considered Possible Value Trap. The stock's GF Value™ is NT$29.89, compared to a current price of NT$20.00 — trading 33.1% below its estimated fair value. The current 14-Day RSI is 51.15 and 2.9% below the Medical Diagnostics & Research industry median of 52.69. TFBS Bioscience's overall GF Score™ is 54/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For TFBS Bioscience (ROCO:6939), the current 14-Day RSI is 51.15 as of Aug. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TFBS Bioscience (ROCO:6939) Overvalued in 2026?
Based on GuruFocus' analysis, TFBS Bioscience stock appears to be undervalued.
The current stock price of NT$20.00 is trading 33.1% below its estimated GF Value™ of NT$29.89.
GuruFocus considers TFBS Bioscience to be Possible Value Trap.
Key valuation signals for ROCO:6939:
14-Day RSI: 51.15
GF Value™: NT$29.89 vs. price of NT$20.00 (33.1% below fair value)
Industry Position: 2.9% below the Medical Diagnostics & Research median (#103 of 219)
No single metric tells the full story. See the ROCO:6939 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TFBS Bioscience Inc is a Contract Research Organization (CRO) providing biological testing in Taiwan. Its services include viral vector manufacturing for cell and gene therapy products and biosafety testing and product release testing for cell and gene therapy products, vaccines, and biologic products.
54GF Score
Get the complete analysis for ROCO:6939
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6939 has been successfully added to your 
